Feature | May 19, 2014

ECG for Pre-Participation Screening of High School Athletes Efficient at Finding Heart Abnormalities

Largest study to use modern interpretation criteria of ECGs led to more accurate detection of cardiac conditions


May 19, 2014 — A new study found that adding an electrocardiogram (ECG) to existing pre-participation screening of high school athletes increases the likelihood of identifying disorders associated with sudden cardiac death. By using modern interpretation criteria, screenings resulted in fewer false-positive rates, which leads to more accurate detection. The findings were presented at Heart Rhythm 2014, the Heart Rhythm Society’s (HRS) 35th annual scientific sessions.

The prospective study was conducted at 23 high schools in the greater Seattle area from October 2010 through June 2013. Competitive athletes ages 13 to 19 underwent a screening protocol that included a heart health questionnaire and physical recommendations based on the current American Heart Assn. (AHA) recommendations, as well as a resting 12-lead ECG interpreted using athlete-specific criteria and limited echocardiogram.

Nearly 5,000 (4,812) athletes were screened, and 23 athletes were identified with a significant abnormality requiring further evaluation. Abnormal history or physical examination findings led to a diagnosis in 61 percent of disorders, and an abnormal ECG led to a diagnosis in 70 percent. The addition of ECG led to detection in seven (30 percent) athletes not otherwise identified by AHA protocol.

“The debate has mostly been focused on whether or not to include ECG screening, and this study shows it is not just about whether or not to include an ECG, but the importance of appropriate ECG interpretation in athletes,” said lead author Jordan M. Prutkin, M.D., MHS, FHRS, assistant professor at the University of Washington School of Medicine Center for Sports Cardiology. “We need to focus future research on how we can further develop better athlete-specific interpretation criteria, which in turn will help reduce sudden cardiac arrest in the young population.”

While the history and physical exam are important and recommended by AHA, the study found that these alone gave more false positive readings than the ECG. The ECG had a significantly lower false positive rate at 3.6 percent, when compared to the history (22.3 percent) and physical exam (14.9 percent). In addition, the ECG was better at positively predicting abnormalities than the history and physical examination. When modern interpretation criteria is used, ECG screening increases the likelihood of detecting disorders associated with sudden cardiac death and may help ease anxiety about the results of the ECG screening and reduce associated costs. An integrated screening protocol using history, physical examination and ECGs should be considered for pre-participation screening in young athletes.

For more information: www.hrsonline.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now